- The 8 States Most Likely to Legalize Marijuana Next
- BlackBerry Is Finally Realizing Smartphones Aren't the Answer
- Express Scripts and AbbVie Drug-Pricing Deal Might Devastate Biotech Bull Market
- Dow 18,000: Why This Market Rally May Never Happen Again
- Gilead Sciences Is Not a Buy; It's Heading Lower on Price War: Jim Cramer
Options expert Tony Pelz outlines a short-biased trade to play Peregrine's decline.
Tony Pelz shows investors how to monitor unusual options trades to manage risk.
Tony Pelz offers an options trading strategy for investing in Sarepta and next month's eteplirsen data presentation.
Tony Pelz debuts a new column focused on using options to invest and trade in biotech stocks.